Skip to main content
SpringerLink
Log in

Neue Therapieoptionen bei retinalen Erkrankungen: Was bringt die Zukunft?

  • Chapter
Glaukom und Makula 2010

  • 954 Accesses

Zusammenfassung

Neue Einblicke in die Pathogenese retinaler Erkrankungen ermöglichen es, erstmals verschiedene pharmakologische Therapieansätze zu verfolgen und zu kombinieren. Im Folgenden sollen aktuelle und zukünftige Therapieoptionen insbesondere der altersabhängigen Makuladegeneration und des diabetischen Makulaödems dargelegt werden, jedoch soll auch aktuellen Therapieentwicklungen seltenerer Netzhauterkrankungen wie beispielsweise der makulären Teleangiektasie Rechnung getragen werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 9.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 19.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Ahmadieh H, Taei R, Soheilian M et al. (2007) Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol 7: 7–10

    Article  Google Scholar 

  • ARC1905 Given Either in Combination Therapy With Lucentis 0,5 mg/Eye in Subjects With Neovascular Age-Reated Macular Degeneration [Identifier NCT00709527]. www.clinicaltrials.gov

  • Beatty S, Koh H, Phil M, Henson D, Boulton M (2000) The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45: 115–134

    Article  PubMed  CAS  Google Scholar 

  • Beatty S, Murray IJ, Henson DB, Carden D, Koh H, Boulton ME (2001) Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population. Invest Ophthalmol Vis Sci 42: 439–446

    PubMed  CAS  Google Scholar 

  • Benz M, Nguyen Q, Chu K et al. (2007) CLEAR-IT-2: Interim results of the phase ii, randomized, controlled doseand interval-ranging study of repeated intravitreal vegf trap administration in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 48: ARVO E-Abstract 4549

    Article  Google Scholar 

  • Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) [Identifier NCT00622726]. www.clinicaltrials.gov

  • Bingaman D, Gu X, Landers R et al. (2007) AL-39324 Is More Potent and Efficacious Against Ocular NV vs. Other RTKi’s. Invest Ophthalmol Vis Sci 48: E-Abstract 1747

    Google Scholar 

  • Bone RA, Landrum JT, Guerra LH, Ruiz CA (2003) Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. J Nutr 133: 992–998

    PubMed  CAS  Google Scholar 

  • Boyer D (2008) SAILOR Study Results. American Academy of Ophthalmology Congress 2008. Atlanta, p 57

    Google Scholar 

  • Brouty-Boye D, Zetter BR (1980) Inhibition of cell motility by interferon. Science 208: 516–518

    Article  PubMed  CAS  Google Scholar 

  • Brown DM, Campochiaro PA, Singh RP et al. (2010) Ranibizumab for macular edema following central retinal vein occlusion six-month primary end point results of a phase III study. Ophthalmology 117: 1124–1133

    Article  PubMed  Google Scholar 

  • Brown DM, Kaiser PK, Michels M et al. (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432–1444

    Article  PubMed  CAS  Google Scholar 

  • Browning AC, Chung AK, Ghanchi F et al. (2005) Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: one-year results of a prospective case series. Ophthalmology 112: 1227–1231

    Article  PubMed  Google Scholar 

  • Bruckner A (2006) Small interfering rna (CAND5) for the treatment of subfoveal choroidal neovascularization due to age-related macular degeneration. Combined Retina Society/Gonin Society Meeting, Cape Town

    Google Scholar 

  • Campochiaro PA, Heier JS, Feiner L et al. (2010) Ranibizumab for macular edema following branch retinal vein occlusion six-month primary end point results of a phase III study. Ophthalmology 117: 1102–1112

    Article  PubMed  Google Scholar 

  • Chakravarthy U, Adamis AP, Cunningham ET Jr et al. (2006) Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113: 1508, e1501–1525

    Google Scholar 

  • Chappelow AV, Kaiser PK (2008) Neovascular age-related macular degeneration: potential therapies. Drugs 68: 1029–1036

    Article  PubMed  CAS  Google Scholar 

  • Charbel Issa P, Holz FG, Scholl HPN (2007) Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 114: 1736–1742

    Article  PubMed  Google Scholar 

  • Charbel Issa P, Finger RP, Holz FG, Scholl HPN (2008) Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol 92: 941–945

    Article  PubMed  CAS  Google Scholar 

  • Charbel Issa P, Finger RP, Kruse K, Baumüller S, Scholl HP, Holz FG (2011) Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol Feb 18. [Epub ahead of print]

    Google Scholar 

  • Chen Z, Mak C, Renick J et al. (2007) A dual VEGFR/JAK2 kinase inhibitor suitable for topical delivery inhibits choroidal neovascularization in mice. Invest Ophthalmol Vis Sci 48: E-Abstract 1469

    Google Scholar 

  • Clark AF, Mellon J, Li XY et al. (1999) Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci 40: 2158–2162

    PubMed  CAS  Google Scholar 

  • Cohen SY (2009) Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 29: 1062–1066

    Article  PubMed  Google Scholar 

  • Coleman H, Chew E (2007) Nutritional supplementation in age-related macular degeneration. Curr Opin Ophthalmol 18: 220–223

    Article  PubMed  Google Scholar 

  • Collier RJ, Patel Y, Martin EA, Dembinska O, Hellberg M, Krueger DS, Kapin MA, Romano C (2011) Agonists at the serotonin receptor (5HT1A) protect the retina from severe photo-oxidative stress. Invest Ophthalmol Vis Sci 52: 2118–2126

    Article  PubMed  CAS  Google Scholar 

  • CoMentis Co (2007) CoMentis initiates phace II clinical trial for AMD eye drop [press release]

    Google Scholar 

  • Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). http://www.med.upenn.edu/cpob/studies/CATT.shtml

  • Complement Inhibition with Eculizumab for the treatment of non-exsudative macular degeneration [Identifier NCT00935883]. www.clinicaltrials.gov

  • Connor KM, SanGiovanni JP, Lofqvist C et al. (2007) Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 13: 868–873

    Article  PubMed  CAS  Google Scholar 

  • Crum R, Szabo S, Folkman J (1985) A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230: 1375–1378

    Article  PubMed  CAS  Google Scholar 

  • D‘Amico D, Bird AC (2004) VEGF Inhibition Study in Ocular Neovascularization-1 (VISION-1): Safety Evaluation from the Pivotal Macugen TM (Pegaptanib Sodium) Clinical Trials. Invest Ophthalmol Vis Sci 45: E-Abstract 2363

    Google Scholar 

  • D‘Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, Yannuzzi L, Zilliox P, Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovasculariszation in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmologe 110: 2372–2383

    Google Scholar 

  • Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J (2004) Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 10: 964–972

    PubMed  CAS  Google Scholar 

  • Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laseror triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117: 1064–1077

    PubMed  Google Scholar 

  • DME And VEGF Trap-Eye: Investigation of Clinical Impact (DA VINCI) [Identifier NCT00789477]. www.clinicaltrials.gov

  • Efficacy and safety of ranibizumab in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia [Identifier NCT01217944]. www.clinicaltrials.gov

  • Engler CB, Sander B, Koefoed P, Larsen M, Vinding T, Lund-Andersen H (1993) Interferon alpha-2a treatment of patients with subfoveal neovascular macular degeneration. A pilot investigation. Acta Ophthalmol (Copenh) 71: 27–31

    Article  CAS  Google Scholar 

  • Ezekowitz RA, Mulliken JB, Folkman J (1992) Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326: 1456–1463

    Article  PubMed  CAS  Google Scholar 

  • Falsini B, Piccardi M, Iarossi G, Fadda A, Merendino E, Valentini P (2003) Influence of short-term antioxidant supplementation on macular function in age-related maculopathy: a pilot study including electrophysiologic assessment. Ophthalmology 110: 51–60; discussion 61

    Article  PubMed  Google Scholar 

  • Finger RP, Charbel Issa P, Ladewig M, Holz FG, Scholl HPN (2008) Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum. Br J Ophthalmol 92: 483–487

    Article  PubMed  CAS  Google Scholar 

  • Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema [NCT00344968]. www.clinicaltrials.gov

  • Fung WE (1991) Interferon alpha 2a for treatment of age-related macular degeneration. Am J Ophthalmol 112: 349–350

    PubMed  CAS  Google Scholar 

  • Gan IM, Ugahary LC, van Dissel JT et al. (2005) Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes Arch Clin Exp Ophthalmol 243: 1186–1189

    Article  PubMed  CAS  Google Scholar 

  • Garrett K, Shen WY, Rakoczy PE (2001) In vivo use of oligonucleotides to inhibit choroidal neovascularization in the eye. J Gene Med 3: 373–383

    Article  PubMed  CAS  Google Scholar 

  • Gasparini G (2001) Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2: 733–740

    Article  PubMed  CAS  Google Scholar 

  • Geographic Atrophy Treatment Study [Identifier NCT00890097]. www.clinicaltrials.gov

  • Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805–2816

    Article  PubMed  CAS  Google Scholar 

  • Group PTfMDS (1997) Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group. Arch Ophthalmol 115: 865–872

    Google Scholar 

  • Group TAS (2001) A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119: 1417–1436

    Google Scholar 

  • Group TES (2002) Anti-VEGF therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase IB results. Association for Research in Vision and Ophthalmology Annual Meeting. Fort Lauderdale, FL, USA. Invest Ophthalmol Vis Sci 2002: E-Abstract

    Google Scholar 

  • Gruber BL, Marchese MJ, Kew R (1995) Angiogenic factors stimulate mast-cell migration. Blood 86: 2488–2493

    PubMed  CAS  Google Scholar 

  • Guba M, von Breitenbuch P, Steinbauer M et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128–135

    Article  PubMed  CAS  Google Scholar 

  • Hall NF, Gale CR, Syddall H, Phillips DI, Martyn CN (2001) Risk of macular degeneration in users of statins: cross sectional study. BMJ 323: 375–376

    Article  PubMed  CAS  Google Scholar 

  • Haller JA, Bandello F, Belfort R Jr et al. (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117: 1134–1146

    Article  PubMed  Google Scholar 

  • Hammond B, Caruso-Avery M (2000) Macular pigment optical density in a Southwestern sample. Invest Ophthalmol Vis Sci 41: 1492–1497

    PubMed  Google Scholar 

  • Heeschen C, Weis M, Aicher A, Dimmeler S, Cooke JP (2002) A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest 110: 527–536

    PubMed  CAS  Google Scholar 

  • Holekamp N (2001) Deficiency of anti-angiogenic pigment epithelial-derived factor in the vitreous of patients with wet age-related macular degeneration. Retina Society Annual Meeting, Chicago

    Google Scholar 

  • Holz F, Wolfensberger TJ, Piguet B, Gross-Jendroska M, Arden GB, Bird AC (1993) Oral zinc-therapy in age-related macular degeneration: a double blind study. Germ J Ophthalmol 2 (Suppl): 391

    Google Scholar 

  • Hruby K (1977) Aussichten und Grenzen der Behandlung seniler Makulopathien mit Phosphatiden. Wien Klin Wschr 89: 439–442

    PubMed  CAS  Google Scholar 

  • Hunt S (2007) Increased dietary intake of omega-3-PUFA reduces pathological retinal angiogenesis. Ophthalmologe 104: 727–729

    Article  PubMed  CAS  Google Scholar 

  • Infliximab, Sirolismus and Daclizumab to Treat Age-Related Macular Degeneration [Identifier NCT00304954]. www.clinicaltrials.gov

  • Institute NE (2008) Age-related Eye Diseases Study 2. www.areds2.org

  • Joussen AM, Rohrschneider K, Reichling J, Kirchhof B, Kruse FE (2000) Treatment of corneal neovascularization with dietary iso-flavonoids and flavonoids. Exp Eye Res 71: 483–487

    Article  PubMed  CAS  Google Scholar 

  • Kaiser PK (2006) Antivascular endothelial growth factor agents and their development_ therapeutic implications in ocular diseases. Am J Ophthalmol 142: 660–668

    Article  PubMed  CAS  Google Scholar 

  • Kaminski MS, Yolton DP, Jordan WT, Yolton RL (1993) Evaluation of dietary antioxidant levels and supplementation with ICAPS-Plus and Ocuvite. J Am Optom Assoc 64: 862–870

    PubMed  CAS  Google Scholar 

  • Karciouglu Z (1982) Zinc in the eye. Surv Ophthalmol 27: 114

    Article  Google Scholar 

  • Kengatharan M, Verghese M, Kiuchi K, Cooke J, Campochiaro P (2007) Nicotinic receptor antagonist mecamylamine reduces laser-induced choroidal neovascularization in C57bl/6j mice. Invest Ophthalmol Vis Sci 48: EAbstract 6016

    Google Scholar 

  • Kleinman ME, Yamada K, Takeda A et al. (2008) Sequence – and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452: 591–597

    Article  PubMed  CAS  Google Scholar 

  • Kleinmann D, Kimm T, Nivaggioli T et al. (2007) Sirolimus Inhibits VEGF-Induced Microvascular Hyperpermeability. Invest Ophthalmol Vis Sci 48: E-Abstract 1422

    Google Scholar 

  • Konner J, Dupont J (2004) Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer 4 (Suppl 2): S81–85

    Article  PubMed  CAS  Google Scholar 

  • Ladewig MS, Karl SE, Hamelmann V, Helb HM, Scholl HP, Holz FG, Eter N (2008) Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 246(1): 17–25

    Article  PubMed  CAS  Google Scholar 

  • Lambert V, Munaut C, Noel A et al. (2001) Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. Faseb J 15: 1021–1027

    Article  PubMed  CAS  Google Scholar 

  • Lockington D, Imrie F, Gillen J, Fitzpatrick A, Willison H (2010) Visual improvement in established central retinal vein occlusion with long-standing macular edema following systemic eculizumab treatment. Can J Ophthalmol 45: 649

    Article  PubMed  Google Scholar 

  • Maier P, Unsoeld AS, Junker B et al. (2005) Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefes Arch Clin Exp Ophthalmol 243: 593–600

    Article  PubMed  CAS  Google Scholar 

  • Majji AB, Hayashi A, Kim HC, Grebe RR, de Juan E Jr (1999) Inhibition of choriocapillaris regeneration with genistein. Invest Ophthalmol Vis Sci 40: 1477–1486

    PubMed  CAS  Google Scholar 

  • Massin P, Bandello F, Garweg JG et al. (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33: 2399–2405

    Article  PubMed  CAS  Google Scholar 

  • Meyer C, Eter N, Holz F, SUSTAIN Study Group (2008) Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. interim results from the Sustain Trial. ARVO 273: A582

    Google Scholar 

  • Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112: 1035–1047

    Article  PubMed  Google Scholar 

  • Miller J, Shima DT, Tolentino M et al. (1995) Inhibition of VEGF prevents ocular neovascularization in a monkey model. Invest Ophthalmol Vis Sci (Suppl): 401

    Google Scholar 

  • Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA (2002) Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 43: 2428–2434

    PubMed  Google Scholar 

  • Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension. [Identifier NCT00605280]. www.clinicaltrials.gov

  • Nakajima M, Cooney MJ, Tu AH et al. (2001) Normalization of retinal vascular permeability in experimental diabetes with genistein. Invest Ophthalmol Vis Sci 42: 2110–2114

    PubMed  CAS  Google Scholar 

  • Nazari H Modarres M, Parvaresh MM, Ghasemi Falavarjani K (2010) Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol 248: 1713–1718

    Article  PubMed  CAS  Google Scholar 

  • Newsome DA, Swartz M, Leone NC, Elston RC, Miller E (1988) Oral zinc in macular degeneration. Arch Ophthalmol 106: 192–198

    PubMed  CAS  Google Scholar 

  • Nguyen QD, Shah SM, Khwaja AA et al. (2010) Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology 117: 2146–2151

    Article  PubMed  Google Scholar 

  • Nozaki M, Raisler B, Mett I et al. (2006) RTP801i: A novel anti-angiogenic strategy superior to and cooperative with VEGF-A blockade in suppressing CNV. Invest Ophthalmol Vis Sci 47: E-Abstract 900

    Google Scholar 

  • Open-Label, Pilot Study of TG10801 in Patients with Choroidal Neovascularisation due to AMD [Identifier NCT00509548]. www.clinicaltrials.gov

  • Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP) [Identifier NCT01232777]. www.clinicaltrials.gov

  • Parodi MB, Iacono P, Papayannis A et al. (2010) Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 128: 437–442

    Article  PubMed  CAS  Google Scholar 

  • Pauleikhoff D, van Kuijk FJ, Bird AC (2001) Makuläres Pigment und altersabhängige Makuladegeneration. Ophthalmologe 98: 511–519

    Article  PubMed  CAS  Google Scholar 

  • Penn JS, Rajaratnam VS, Collier RJ, Clark AF (2001) The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 42: 283–290

    PubMed  CAS  Google Scholar 

  • Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema [NCT00490815]. www.clinicaltrials.gov

  • Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD. www.clinicaltrials.gov

  • Phase 2 Study of an Ocular Sirolimus Formulation in Combination with Lucentis in Patients with Age-related Macular Degeneration [Identifier NCT00766337]. www.clinicaltrials.gov.

  • Phase I Dose Escalation Study of PF-04523655 in Subjects with choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration [Identifier NCT00725686]. www.clinicaltrials.gov

  • Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration With Verteporfin: One-Year Results of 2 Randomized Clinical Trials – TAP Report. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Arch Ophthalmol 117: 1329–1345

    Google Scholar 

  • Prävention des Sehverlustes bei Patienten mit altersabhängiger Makuladegeneration durch intravitreale Injektion vonBevacizumab und Ranibizumab. http://www.pharmakologie-bremen.de/index.php/klinische-forschung/vibera

  • Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab (VIBERA). http://www.clinicaltrials.gov/ct2/show/NCT00559715

  • Prospective, Randomized, Multi-Center, Comparator Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema (DEGAS) [Identifier NCT00701181]. www.clinicaltrials.gov

  • Querques G (2009) Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema Acta Ophthalmol 87: 623–630

    CAS  Google Scholar 

  • Radu RA, Han Y, Bui TV et al. (2005) Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci 46: 4393–4401

    Article  PubMed  Google Scholar 

  • Randomised Controlled Trial of Alternative Treatments to Inhibit VEGF in Age-Related Choroidal Neovascularisation. http://www.controlled-trials.com/ISRCTN92166560

  • Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients with Pseudoxanthoma Elasticum (PXE) [Identifier NCT00510965]. www.clinicaltrials.gov

  • Rasmussen H, Chu KW, Campochiaro P et al. (2001) Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 12: 2029–2032

    PubMed  CAS  Google Scholar 

  • Rechtman E, Danis RP, Pratt LM, Harris A (2004) Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 88: 344–347

    Article  PubMed  CAS  Google Scholar 

  • Renno RZ, Youssri AI, Michaud N, Gragoudas ES, Miller JW (2002) Expression of pigment epithelium-derived factor in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 43: 1574–1580

    PubMed  Google Scholar 

  • Rich RM, Rosenfeld PJ, Puliafito CA et al. (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26: 495–511

    Article  PubMed  Google Scholar 

  • Rosenfeld PJ, Brown DM, Heier JS et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419–1431

    Article  PubMed  CAS  Google Scholar 

  • Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36: 331–335

    PubMed  Google Scholar 

  • Safety and Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD [Identifier NCT00499590]. www.clinicaltrials.gov

  • Safety and Efficacy Study Of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) (ADVANCE) [Idenitfier NCT00138632]. www.clinicaltrials.gov

  • Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema [Identifier NCT00306904]. www.clinicaltrials.gov

  • Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers [Identifier NCT01072214]. www.clinicaltrials.gov

  • Saishin Y, Takahashi K, Lima e Silva R et al. (2003) VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195: 241–248

    Article  PubMed  CAS  Google Scholar 

  • Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44: 4473–4480

    Article  PubMed  Google Scholar 

  • Scholl HP, Charbel Issa P, Walier M et al. (2008) Systemic complement activation in age-related macular degeneration. PLoS ONE 3: e2593

    Article  PubMed  Google Scholar 

  • Schütt F, Pauleikhoff D, Holz FG (2002) Vitamine und Spurenelemente bei altersabhängiger Makuladegeneration. Aktuelle Empfehlungen, basierend auf den Resultaten der AREDS-Studie. Ophthalmologe 99: 301–303

    Article  PubMed  Google Scholar 

  • Shalinsky DR, Brekken J, Zou H et al. (1999) Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 878: 236–270

    Article  PubMed  CAS  Google Scholar 

  • Shen J, Samul R, Silva RL et al. (2006) Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 13: 225–234

    Article  PubMed  CAS  Google Scholar 

  • Slakter JS, Bochow TW, D‘Amico DJ et al. (2006) Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 113: 3–13

    Article  PubMed  Google Scholar 

  • Spaide RF, Ho-Spaide WC, Browne RW, Armstrong D (1999) Characterization of peroxidized lipids in Bruch‘s membrane. Retina 19: 141–147

    Article  PubMed  CAS  Google Scholar 

  • Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110: 1517–1525

    Article  PubMed  Google Scholar 

  • Spaide RF, Sorenson J, Maranan L (2005) Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112: 301–304

    Article  PubMed  Google Scholar 

  • Spaide RF, Laud K, Fine HF et al. (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26: 383–390

    Article  PubMed  Google Scholar 

  • Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE (2000) Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 157: 135–144

    Article  PubMed  CAS  Google Scholar 

  • Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A (1998) Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 39: 2194–2200

    PubMed  CAS  Google Scholar 

  • Stokes CL, Rupnick MA, Williams SK, Lauffenburger DA (1990) Chemotaxis of human microvessel endothelial cells in response to acidic fibroblast growth factor. Lab Invest 63: 657–668

    PubMed  CAS  Google Scholar 

  • Study of ARC1905 in Subjects With Dry Age-Reated Macular Degeneration [Identifier NCT00950638]. www.clinicaltrials.gov

  • Study of Fenretinide in the Treatment of Geographic Atrophy Associated with dry age-related Macular degeneration [Identifier NCT00429936]. www.clinicaltrials.gov

  • Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects with Geographic Atrophy [Identifier NCT01002950]. www.clinicaltrials.gov

  • Study to Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Eye Drops in Adult Subjects with Neovascular AMD [Identifier NCT00612456]. www.clinicaltrials.gov

  • Study to Evaluate The Safety, Tolerability and PK of Pazopanib Eye Drops in Healthy Adult and Elderly Subjects [Identifier NCT00463320]. www.clinicaltrials.gov

  • Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration. www.clinicaltrials.gov

  • Takahashi K, Saishin Y, Saishin Y, King AG, Levin R, Campochiaro PA (2009) Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol 127: 494–499

    Article  PubMed  CAS  Google Scholar 

  • The CATT Research Group (2011) Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med 2011; 364:1897–1908. http://www.nejm.org/toc/nejm/364/20/

  • The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated with Age-Related Macular Degeneration [Identifier NCT00485394]. www.clinicaltrials.gov

  • Treatment of Corneal Neovascularisation with Topical Pazopanib [Identifier NCT01257750]. www.clinicaltrials.gov

  • Umeda N, Kachi S, Akiyama H et al. (2006) Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. Mol Pharmacol 69: 1820–1828

    Article  PubMed  CAS  Google Scholar 

  • VEGF Trap Eye: Investigation of Efficacy and Safety in Central Vein Occlusion (Copernicus) [Identifier NCT00943072]. www.clinicaltrials.gov

  • VEGF Trap Eye: Investigation of Efficacy and Safety in Central Vein Occlusion (Galileo) [Identifier NCT01012973]. www.clinicaltrials.gov

  • VEGF Trap-Eye in choroidal neovascularization Secondary to Pathologic myopia (mCNV) (Myrror) [Identifier NCT01249664]. www.clinicaltrials.gov

  • VEGF-Trap Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration [Identifier NCT00637377]. www.clinicaltrials.gov

  • WALTZ – Wet Age-Related Macular Degeneration (AMD) AL 39324 Treatment Examnition [Identifier NCT00992563]. www.clinicaltrials.gov

  • Wang B, Zou Y, Li H, Yan H, Pan JS, Yuan ZL (2005) Genistein inhibited retinal neovascularization and expression of vascular endothelial growth factor and hypoxia inducible factor 1 in a mouse model of oxygen-induced retinopathy. J Ocul Pharmacol Ther 21: 107–113

    Article  PubMed  Google Scholar 

  • Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK (2011) Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology 118: 176–183

    Article  PubMed  Google Scholar 

  • Zahn G, Vossmeyer D, Stragies R et al. (2009) Preclinical evaluation of the novel small-molecule integrin α5β1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch Ophthalmol 127: 1329–1335

    Article  PubMed  CAS  Google Scholar 

  • Zahn G, Vossmeyer D, Stragies R, Wills M, Wong C, Knolle J (2007) JSM6427, a small molecule integrin alpha5beta1 inhibitor for inhibition of ocular angiogenesis. Invest Ophthalmol Vis Sci 48: E-Abstract 3430

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Münster, Domagkstr. 15, 48149, Münster

    Dr. med. Florian Alten & Prof. Dr. med. Nicole Eter

Authors
  1. Dr. med. Florian Alten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Nicole Eter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Alten, F., Eter, N. (2011). Neue Therapieoptionen bei retinalen Erkrankungen: Was bringt die Zukunft?. In: Glaukom und Makula 2010. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-22054-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-22054-8_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-22053-1

  • Online ISBN: 978-3-642-22054-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation